CYCLOSPORIN A IN RHEUMATOID ARTHRITIS

每日口服环孢菌素A（CSA）治疗慢性乙型肝炎的疗效和毒性 活动性类风湿关节炎患者正在接受评估， 低剂量（lmg/kg/天）对比高剂量的6个月双盲研究 剂量（10 mg/kg/天）CSA。 每周监测毒性， 前2个月，然后每2周一次，直到6个月。 疾病 每两个月对活动进行一次评估。 患者不 在6岁时，疾病活动性至少改善40% 月从研究中删除，而那些有40%或 更大的反应持续6个月的药物 疗法 CSA对T细胞各项指标的影响 外周血和滑膜内淋巴细胞功能 在所有患者中进行研究。

The efficacy and toxicity of daily, oral cyclosporin A (CSA) in patients with active rheumatoid arthritis is being evaluated in a 6 month double-blind study of low dose (lmg/kg/day) versus high dose (10mg/kg/day) CSA. Toxicity is monitored weekly for the first 2 months and then every 2 weeks until 6 months. Disease activity is assessed on a bi-monthly basis. Patients who do not develop at least a 40% improvement in disease activity at 6 months are dropped from the study, while those with a 40% or greater response continue for an additional 6 months of drug therapy. The effects of CSA on various measures of T lymphocyte function in peripheral blood and within the synovium is studied in all patients.